Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localizing treatment to the tumor microenvironment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] Clinical Pipeline - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CX-2051 has potential applications in various EpCAM-expressing epithelial cancers, including colorectal cancer (CRC), and was developed in collaboration with ImmunoGen [3] - CX-801 is designed for broad applicability in both immuno-oncology sensitive and insensitive tumors [3] Strategic Collaborations - CytomX has established partnerships with leading companies in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3] Upcoming Events - Management will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 [2] - A live webcast of the presentations will be available on CytomX's website, and management will hold one-on-one meetings with registered investors [2]

Core Insights - CytomX Therapeutics is advancing its CX-2051 Phase 1 study for colorectal cancer (CRC) with 73 patients enrolled and aims to provide a data update in Q1 2026 [1][2][6] - Patient safety is prioritized as the study continues with dosing across all expansion doses [2][6] Company Overview - CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing conditionally activated, masked biologics for cancer treatment [4] - The company utilizes its PROBODY therapeutic platform to create localized therapies, including antibody-drug conjugates (ADCs) and immune modulators [4] - Current clinical-stage pipeline includes CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM), and CX-801, a masked interferon alpha-2b PROBODY cytokine [4] CX-2051 Program Status - The CX-2051 study has enrolled approximately 20 patients at each of the three expansion doses: 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, administered every three weeks [6] - A serious adverse event (Grade 5 treatment-related acute kidney injury) was reported, but the study continues with support from the Safety Review Committee [6] Strategic Collaborations - CytomX has established partnerships with leading oncology companies, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [4]

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing conditionally activated, masked biologics localized to the tumor microenvironment [3] - The company utilizes its PROBODY® therapeutic platform to create safer and more effective cancer therapies [3] - CytomX's pipeline includes therapeutic candidates such as CX-2051 and CX-801, with CX-2051 being a masked, conditionally activated ADC targeting epithelial cell adhesion molecule (EpCAM) [3] Financial Results Announcement - CytomX will report its first quarter financial results on May 12, 2025, before the U.S. markets open [1] - A conference call and webcast will follow the announcement at 8:00 a.m. ET / 5:00 a.m. PT [1] Strategic Collaborations - The company has established collaborations with major oncology leaders including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3]